Free Trial
Thank you for registering! Take a moment to confirm your subscription to MarketBeat Daily Ratings so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
TSE:GEN

GeneNews (GEN) Stock Price, News & Analysis

→ The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad)
Free GEN Stock Alerts
C$0.15
+0.01 (+7.14%)
(As of 06/25/2019)
Compare
Today's Range
C$0.14
▼
C$0.15
50-Day Range
C$0.15
▼
C$0.15
52-Week Range
C$0.03
▼
C$0.21
Volume
473,147 shs
Average Volume
1.48 million shs
Market Capitalization
C$25.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
GEN stock logo

About GeneNews Stock (TSE:GEN)

GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.

GEN Stock Price History

GEN Stock News Headlines

May 16, 2024 | washingtonpost.com
GeneNews: Q1 Earnings Snapshot
January 18, 2024 | msn.com
Vertex, Crispr Get Second FDA Approval for Gene Therapy
January 17, 2024 | msn.com
Gene-editing treatment from Vertex and CRISPR cleared for second rare blood disorder
January 17, 2024 | msn.com
FDA expands use of newly approved CRISPR therapy
January 16, 2024 | washingtonpost.com
Ohio St hires Texas A&M athletic director Ross Bjork to replace the retiring Gene Smith
November 27, 2023 | msn.com
Mutated gene thought to exist in just 4% of people could ‘help tackle obesity’
November 18, 2023 | nytimes.com
Sickle-Cell Treatment Created With Gene Editing Wins U.K. Approval
November 17, 2023 | msn.com
UK authorizes gene therapy for blood disorders in world first
November 16, 2023 | msn.com
Mac Jones Losing Support of Patriots Teammates After Being Benched for Third Time, Report
November 16, 2023 | usatoday.com
Gene Frenette: Mac Jones' decline with Patriots also a product of Bill Belichick negligence
October 31, 2023 | msn.com
Sarepta Seeks Broader Approval for Gene Therapy Even After Drug Trial Fizzled
October 31, 2023 | wsj.com
Sarepta Therapeutics Stock Dives After New Gene Therapy Data
October 31, 2023 | msn.com
FDA panel considers gene therapy as a potential cure for the sickest sickle cell patients
March 27, 2023 | marketwatch.com
Oncology Molecular Diagnostics Market by 2031
March 19, 2023 | marketwatch.com
Global Colorectal Cancer Diagnostic Market Industry Insights, Drivers, Top Trends, Global Analysis, Forecast and Opportunities to 2030 By VMReports
January 5, 2023 | thestreet.com
Biotech Stock Mailbag: GenVec
February 23, 2022 | investing.com
StageZero Life Sciences Ltd (SZLS)
See More Headlines

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
Current Symbol
TSE:GEN
CUSIP
N/A
CIK
N/A
Web
www.genenews.com
Phone
+1-905-7392030
Fax
N/A
Employees
15
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.10
Quick Ratio
0.05

Sales & Book Value

Annual Sales
C$234,592.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
145.00
Book Value
C($0.06) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
169,963,000
Free Float
N/A
Market Cap
C$25.49 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. James R. Howard-Tripp
    Exec. Chairman & CEO
  • Ms. Joanna M. Halsey Esq.
    Gen. Counsel, Chief Compliance Officer & HR Director of IDL
  • Prof. Choong-Chin Liew Ph.D.
    Co-Founder
  • Mr. Warren Whitehead (Age 67)
    Chief Accountant
  • Mr. David Suria
    Sr. Scientist

Key Competitors

View All Competitors

GEN Stock Analysis - Frequently Asked Questions

How have GEN shares performed in 2024?

GeneNews' stock was trading at C$0.15 on January 1st, 2024. Since then, GEN stock has increased by 0.0% and is now trading at C$0.15.
View the best growth stocks for 2024 here.

What other stocks do shareholders of GeneNews own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GeneNews investors own include StorageVault Canada (SVI), American Airlines Group (AAL), Aareal Bank (ARL), Broadcom (AVGO), Aspen Technology (AZPN), British American Tobacco (BATS), Cronos Group (CRON) and Edwards Lifesciences (EW).

How do I buy shares of GeneNews?

Shares of GEN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:GEN) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Shocking: One AI startup's revenue could surge 4,735%
Manward Press
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
Next President (Not Trump. Not Biden.)
The Freeport Society
Elon’s New Device is About to Shock the World
InvestorPlace
"The Biggest Drug Ever" Is Coming
Behind the Markets
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders
Dems have chosen Biden replacement?
Paradigm Press
Bill Gates is all about this tiny $2 stock
Timothy Sykes